A multicenter study of recombinant human erythropoietin (epoetin α) in the management of anemia in cancer patients receiving chemotherapy

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 949-957

  Pawlicki, Marek ^a,b   Jassem, Jacek ^a,b   Bösze, Peter ^a,c   Lotan, Chana ^a,d   Kurteva, Galena P ^a,e   Siddiqui, Mohammed ^a,f   Kosmidis, Paris A ^a,g   Rigatos, Gerasimos A ^a,h   Kansu, Emin ^a,i   Durkovic, Pavol ^a,j   Aziz, Zeba ^a,k   Al Idrissi, Hassan ^a,l   Roth, Anton ^a,m   Cozma, Gabriel ^a,n  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e National Oncology Center Bulgaria   (Bulgaria)

^f TAWAM HOSPITAL   (United Arab Emirates)

^g METAXA CANCER HOSPITAL   (Greece)

^h SAINT SAVVAS HOSPITAL   (Greece)

ⁱ HACETTEPE UNIVERSITY   (Turkey)

^j CANCER RESEARCH INSTITUTE   (Slovakia)

^k JINNAH HOSPITAL   (Pakistan)

^l IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^m Inst for Tumours and Similar Dis   (Croatia)

ⁿ Cilag AG   (Switzerland)

more..

Author keywords

Anemia; Cancer; Chemotherapy; Epoetin ; Platinum

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; HEMOGLOBIN; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 14444276037     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00006     Document Type: Article

References (20)

1. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Patbol Lab Meet 1994; 118: 371-9.
2. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with anemia of cancer. New Engl J Med 1990; 322: 1689-92.
3. Doweiko JP, Goldberg MA. Erythropoietin therapy in cancer patients. Oncology 1991; 5: 31-7.
4. Jelkmann W, Wolf M, Fandrey J. Inhibition of erythropoietin production by cytokines and chemotherapy may contribute to the anemia in malignant diseases. In: Vaupel P, ed. Oxygen transport to tissue XV. New York: Plenum Press 1994: 525-30.
5. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 1987; 67: 11-7.
6. Schapira L, Antin JH, Ransil BJ, et al. Seram erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990; 76: 2354-9.
7. Rothmann SA, Paul P, Weick JK, et al. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning 1985; 3: 415-23.
8. Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin (epoetin alfa) for the treatment of the anemia of cancer. In: Murphy MJ, ed. Blood cell growth factors: their present and future use in hematology and oncology (Proc Reijing Symp). Dayton, OH: Alpha Medical Press 1991: 121-41.
9. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anaemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9: 2021-6.
10. Abels R. Erythropoietin for anaemia in cancer patients. Eur Cancer 1993; 29A (suppl 2): S2-8.
11. Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4: 161-7.
12. Case DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801-6.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
14. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer 1991; 68: 1101-5.
15. Onat H, Inanc SE, Dalay N, et al. Effect of cisplatin on erythropoietin and iron changes. Eur J Cancer Part A Gen Top 1993; 29A: 777.
16. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21 (suppl 3): 21-8.
17. Nelson RA, Guilfoyle MC, Abels RI, et al. Long-term treatment of anemic cancer patients with recombinant human erythropoietin. Blood 1992; 80 (suppl 1): 284A (abstr 1126).
18. Sheingold S, Churchill D, Muirhead N, et al. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Soc Sci Med 1992; 34: 983-91.
19. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. PharmacoEconomics 1992; 1: 346-56.
20. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia with multiple myeloma. New Engl J Med 1990; 332: 1693-9.